Bromodomain and extra-terminal protein inhibitor combination therapy

Patent metadata

Field	Value
Publication number	US-10166227-B2
Application number	US-201715796571-A
Country	US
Kind code	B2
Filing date	Oct 27, 2017
Priority date	Oct 27, 2016
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

First claim

We claim:

1. A method for treating cancer or neoplastic disease comprising administering to a human patient a therapeutically effective amount of at least one bromodomain and extra-terminal protein (BET) inhibitor, and a therapeutically effective amount of at least one chemotherapeutic agent that does not directly inhibit BET, wherein the BET inhibitor is 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one or a pharmaceutically acceptable salt thereof, and the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel.

2. The method of claim 1 , wherein administering the BET inhibitor and the chemotherapeutic agent results in a synergistic reduction in cell proliferation in a tumor of the patient or a synergistic increase in apoptosis in a tumor of the patient compared with either the BET inhibitor or the chemotherapeutic agent when administered alone.

3. The method of claim 1 , wherein the therapeutically effective amount the BET inhibitor and chemotherapeutic agent when used together is at least 50% lower than the therapeutically effective amount of each when the BET inhibitor and chemotherapeutic agent are used individually.

4. The method of claim 1 , wherein the BET inhibitor and chemotherapeutic agent are administered sequentially.

5. The method of claim 1 , wherein the BET inhibitor and chemotherapeutic agent are administered at the same time.

6. A combination of active agents for treating cancer or neoplastic disease, comprising a therapeutically effective amount of at least one bromodomain and extra-terminal protein (BET) inhibitor and a therapeutically effective amount of at least one chemotherapeutic agent that does not directly inhibit BET, wherein the BET inhibitor is 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one or a pharmaceutically acceptable salt thereof, and the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel.

7. The combination of claim 6 , wherein the combination of the BET inhibitor and the chemotherapeutic agent provides a synergistic reduction in cell proliferation in a tumor of the patient or a synergistic increase in apoptosis in a tumor of a patient as compared with either the BET inhibitor or the chemotherapeutic agent alone.

8. The combination of claim 6 , wherein the therapeutically effective amount BET inhibitor and chemotherapeutic agent used in combination is at least 50% lower than the therapeutically effective amount of each of the BET inhibitor and chemotherapeutic agent when used individually.

9. Use of a combination of at least one bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent that does not directly inhibit BET in the treatment of cancer or neoplastic disease in a patient, comprising administering to the patient a therapeutically effective amount of at least one BET inhibitor and administering to the patient at least one chemotherapeutic agent that does not directly inhibit BET, wherein the BET inhibitor is 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one or a pharmaceutically acceptable salt thereof, and the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel.

10. The use as in claim 9 , wherein use of the combination provides a synergistic effect in reducing cell proliferation or increasing apoptosis in a tumor of the patient compared with either use of the BET inhibitor alone or use of the chemotherapeutic agent alone.

11. The use as in claim 10 , wherein the synergistic effect of the combination is achieved using at least 50% less of each of the BET inhibitor and the chemotherapeutic agent.

Assignees

• Celgene Quanticel Res Inc

Inventors

• Cho Robert
• Stafford Jeffrey Alan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/495

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K38/15

  Depsipeptides; Derivatives thereof · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title